Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05293639 · ClinicalTrials.gov registry record · NA
Assessment of Safety and Effectiveness in Treatment Management of Atrial Fibrillation With the BWI IRE Ablation System
A NA study, sponsored by Biosense Webster.
- Completed
- Registry status
- NA
- Development phase
- 362
- Enrollment target
NCT05293639 is a NA study that has completed, run by Biosense Webster. The registered enrollment target is 362 participants.
The verdict
NCT05293639, a NA study, has completed, sponsored by Biosense Webster.
- COMPLETED
- Registry status
- NA
- Development phase
- 362 participants
- Enrollment target
Study Summary
To demonstrate the safety and 12-month effectiveness of the VARIPULSE™ Catheter when used in conjunction with the TRUPULSE™ Generator for pulmonary vein isolation (PVI) in the treatment of subjects with symptomatic paroxysmal atrial fibrillation.
Interventions
- DEVICE Pulse Field Ablation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 362 participants |
| Start Date | 2022-04-18 |
| Est. Completion | 2023-12-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05293639
The ClinicalTrials.gov registry entry for NCT05293639 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 362 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biosense Webster, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pulse Field Ablation is the first listed.
NCT05293639 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05293639 about?
NCT05293639 is a clinical study titled "Assessment of Safety and Effectiveness in Treatment Management of Atrial Fibrillation With the BWI IRE Ablation System". To demonstrate the safety and 12-month effectiveness of the VARIPULSE™ Catheter when used in conjunction with the TRUPULSE™ Generator for pulmonary vein isolation (PVI) in the treatment of subjects with symptomatic paroxysmal atrial fibrillation.
What is the current status of trial NCT05293639?
This trial is currently completed. It is a NA study. The enrollment target is 362 participants. The study started on 2022-04-18. Estimated completion is 2023-12-11.
What interventions are being tested in trial NCT05293639?
The interventions under investigation include: Pulse Field Ablation (DEVICE).
Who is sponsoring clinical trial NCT05293639?
This trial is sponsored by Biosense Webster, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.